<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02967484</url>
  </required_header>
  <id_info>
    <org_study_id>201507001-08</org_study_id>
    <nct_id>NCT02967484</nct_id>
  </id_info>
  <brief_title>Acupuncture Lowering Blood Pressure for Secondary Prevention of Stroke</brief_title>
  <official_title>Acupuncture Lowering Blood Pressure for Secondary Prevention of Stroke: Study Protocol for a Multicenter, Pragmatic,Randomized Controlled, Assessor-blinded Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>State Administration of Traditional Chinese Medicine of the People's Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the effects of acupuncture method on the recurrence of ischemic stroke
      patients.Half of participants will receive &quot;Huo Xue San Feng&quot; acupuncture combining 1
      antihypertensive medication on the routine ischemic stroke treatments' basis. While the other
      half will receive 1 antihypertensive medication and basic treatments for ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Under recuiting 480 patients come from 5 hospitals in China.Eligible patients will be
      randomly assigned into 2 groups: treatment group and control group. The treatment group will
      receive &quot;Huo Xue San Feng&quot; acupuncture combining 1 antihypertensive medication on the routine
      ischemic stroke treatments' basis. The control group will receive 1 antihypertensive
      medication and basic treatments for ischemic stroke. &quot;Huo Xue San Feng&quot; acupuncture will be
      given six sessions weekly for the first 6 weeks and three times weekly for the next 6 weeks.
      A 9-month follow-up will thereafter be conducted. Antihypertensive medications will be
      adjusted based on BP levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effects of Acupuncture on Reccurence of Ischemic Stroke</measure>
    <time_frame>1 year after enrollment</time_frame>
    <description>The effects of acupuncture on reccurence of ischemic stroke assessed by China's Guidelines of Diagnosis and Treatment of Acute Ischemic Stroke 2014 and China's Guidelines of Diagnosis and Treatment of Cerebral Hemorrhage 2014.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour ambulatory blood pressure</measure>
    <time_frame>the first day、6 weeks、12 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Blood Pressure by Electronic Sphygmomanometer</measure>
    <time_frame>1 year after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antihypertensive Drug Stop/Resumption/Increasing Rate</measure>
    <time_frame>1 year after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitric Oxide(NO)</measure>
    <time_frame>the first day、12 weeks,6 months after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelin(ET)</measure>
    <time_frame>the first day、12 weeks,6 months after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cardiac Color Doppler Ultrasonography</measure>
    <time_frame>the first day、12 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid Color Ultrasonography</measure>
    <time_frame>the first day、12 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Color Doppler Ultrasonography</measure>
    <time_frame>the first day、12 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Extremity Color Ultrasonography</measure>
    <time_frame>the first day、12 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCM syndrome score</measure>
    <time_frame>the first day、6 weeks、12 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36-item Health Survey (SF-36)</measure>
    <time_frame>the first day、6 weeks、12 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale (NIHSS)，as well as Barthel Index (BI) scale</measure>
    <time_frame>the first day、12 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Essen stroke risk score (ESRS)</measure>
    <time_frame>the first day、1 year after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-caused Morality</measure>
    <time_frame>1 year after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum homocysteine（Hcy）</measure>
    <time_frame>the first day、12 weeks,6 months after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble CD40L（sCD40L）</measure>
    <time_frame>the first day、12 weeks,6 months after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copeptin</measure>
    <time_frame>the first day、12 weeks,6 months after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will recieve the therapy as follows: &quot;Huo Xue San Feng&quot; acupuncture method+Routine care for ischemic stroke+One type of antihypertensive medication.
Intervention:Acupuncture(choosing the bilatral acupoint: Renying(ST9),Hegu(L14), Taichong(LR3),Quchi(LI11),Zusanli(ST36))+Drugs(one type of antihypertensive medicine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants recieve the therapy as follows:Routine care for ischemic stroke +One type of antihypertensive medication.
Intervention:Acupuncture(choosing the acupoint: Neiguan(PC6),Renzhong(10), Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).)+Drugs(one type of antihypertensive medicine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>acupuncture</intervention_name>
    <description>&quot;Huo Xue San Feng&quot; acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36).
Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).
Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic.
The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the first time ischemic stroke

          -  Patients meet the TCM diagnosis standard of Stroke

          -  Patients meet the diagnosis standard of hypertension, taking only 1 type of
             antihypertensive drugs for at least 2 weeks before admission,corresponding to systolic
             pressure ranging from 140 to 160mmHg and Diastolic ranging from 90-100mmHg.

          -  The course of Ischemic stroke ranging from 2 weeks to 6 weeks .

          -  Men or Women Aged between 35 and 70 years old.

          -  Patients who are willing to participate in our clinical trial agree to sign the
             informed consent form.

        Exclusion Criteria:

          -  Patients who have been diagnosed with secondary hypertension.

          -  Patients have taken beta blockers or diuretics or non dihydropyridine calcium channel
             blocker （NDHP-CCB）for a long time because of cardiovascular disease.

          -  Patients who taking 1 type of antihypertensive drugs,blood pressure under 140/90mmHg.

          -  Patients accompanied with other neurological disorders,such as epilepsy, peripheral
             nerve injury,

          -  Patients accompanied with severe medical condition such as severe hematopoietic system
             disease, coagulation dysfunction and malignant tumor.

          -  Patients accompanied with diabetic nephropathy,severe liver and renal
             insufficiency,severe cardiac or pulmonary dysfunction,severe arrhythmia.

          -  Patients who have occured skin infections near the acupoint location.

          -  Pregnant or breast-feeding women.

          -  Patients who currently participate in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuemin Shi</last_name>
    <role>Study Director</role>
    <affiliation>The First Teaching Hospital of Tianjin University of TCM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yuzheng Du</last_name>
    <phone>13702088266</phone>
    <email>drduyuzheng11@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing Traditional Chinese Medicine Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhuxing Wang</last_name>
      <phone>+8613883413646</phone>
      <email>wzhuxing1963@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MIANYANG Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Mianyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiuli Yuan</last_name>
      <phone>+8613881109129</phone>
      <email>13881109129@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LONGHUA Hospital Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Pei</last_name>
      <phone>+8618917763082</phone>
      <email>jianpei99@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Bao'an Traditional Chinese Medicine Hospital Group</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peng Zhou</last_name>
      <phone>+8613714077462</phone>
      <email>77103698@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Teaching Hospital of Tianjin University of TCM</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuzheng Du</last_name>
      <phone>+8613702088266</phone>
      <email>drduyuzheng11@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Yuzheng Du</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Acupuncture</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Second prevention of Stroke</keyword>
  <keyword>Efficacy</keyword>
  <keyword>RCT</keyword>
  <keyword>Study protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

